Page 74 - 89Zr-Immuno-PET:Towards a Clinical Tool to Guide Antibody-based Therapy in Cancer
P. 74
Chapter 4
and visually scored. After 1 cycle of T-DM1 an early metabolic response was evaluated by FDG-PET. Clinical outcome after treatment with 3 cycles of T-DM1 was evaluated by CT.
Figure 2. Patterns of HER2-PET/CT confronted with FDG-PET/CT, maximum intensity projection. Lesion uptake was considered pertinent when visually higher than blood pool.
(A) entire tumor load showed pertinent tracer uptake (B) dominant part of tumor load showed tracer uptake (C) minor part of tumor load showed tracer uptake (D) entire tumor load lacked tracer uptake
Reprinted with permission from “Gebhart, G., Lamberts, L.E., Wimana, Z., Garcia, C., Emonts, P., Ameye, L., et al. (2015). Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial. Epub ahead of print. Ann Oncol. doi: 10.1093/annonc/mdv577”
72
